“We are very fortunate to have Dimitrios Mantzilas joining us from Bayer and ensuring a smooth transition in the CTO function. Dimitrios has a long-standing experience in various aspects of radiopharmaceutical development and brings the necessary skill set to guide future growth, strengthen our technology platform and drive our development strategy, further building on the work of Matthias Friebe, who has been instrumental in the optimization and upscaling of our CMC processes over the past years.”, said Ruth Devenyns, CEO of Precirix.
Dimitrios Mantzilas obtained his Master’s degree in Biochemistry at the University of Oslo, where he subsequently became responsible for core technology laboratories in various positions. Following his academic career, he joined GE Healthcare in 2005 where he contributed to the research and development of multiple PET-Imaging tracers and played an important role in technology development (FASTlab) and the commercialization of Vizamyl (visualization of β-amyloid neuritic plaque density). In 2013, Dimitrios joined Algeta to lead the Radiopharmaceutical Development department. Following the acquisition of Algeta by Bayer in 2014, he established a global team to work on the development of radiopharmaceuticals and thus became one of the pioneers in the field of CMC development of targeted alpha pharmaceuticals. His contribution was critical in bringing multiple radiopharmaceutical drug candidates to the clinic, including the establishment of a global supply and manufacturing network.
On his appointment, Dimitrios Mantzilas commented: “I am very excited to join the Precirix team. I have a strong belief in the technology, the assets, the leadership team and the highly talented and skilled employees. This decade is the decade of the radiopharmaceuticals and I look forward to our journey in the development of these novel life-changing treatments."
About Precirix NV
Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose for treatment.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.